Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab access study in selected rare adult cancers
2016-002260-14Phase 2Completed
- Sponsor
- Unicancer
- Start
- Apr 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in soft tissue sarcoma (STS), Visceral sarcoma, bone cancer and 5 more, sponsored by Unicancer. Primary endpoint: Objective response rate. Started Apr 2017; status: completed.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)Visceral sarcomabone cancerovarian cancerprimary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on 2016-002260-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002260-14.